Abcuro, Inc. | MedPath

Abcuro Secures $200M Series C Funding to Advance Novel IBM Treatment Ulviprubart

3 months ago

• Abcuro has raised $200 million in Series C financing led by NEA to advance ulviprubart, a first-in-class monoclonal antibody treatment for inclusion body myositis (IBM). • The funding will support completion of the Phase 2/3 MUSCLE trial for ulviprubart, preparation for BLA filing, and commercial launch activities, with initial data expected in early 2026. • Ulviprubart targets KLRG1 to selectively deplete cytotoxic T cells and has received orphan drug designation from both FDA and EMA for treating IBM, which affects over 50,000 patients across US and Europe.